Should we apply?
7 questions about Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required). The first ones are deal-breakers: grant professionals check them before writing anything. We filled in what we know. Change anything that's wrong.